Doctoral Researchers in Medicine

Bertram Linderkamp

Supervisor: Prof. Dr. Leif-Erik Sander, Charité - Universitätsmedizin Berlin Med. Klinik m.S. Infektiologie und Pneumologie (04.2018-12.2019)


Dissecting innate responses of dendritic cells to bood-stage and pre-blood-stage Plasmodium falciparum


Dendritic cell responses to Plasmodium falciparum will be characterized in various genetic backgrounds using a newly-established cell culture model-system and human primary cells. In addition to standard immunology readouts (ELISA, FACS), single-cell whole-transcriptome analysis will afford insights into heterogeneous activation profiles of DCs after plasmodium challenge.

Clara Bergmann 

Supervisor: Prof. Dr. Frank Mockenhaupt, Charité - Universitätsmedizin Berlin Institute of Tropical Medicine and International Health (04.2018-12.2019)


Characterization of Plasmodium falciparum artemisinin resistance in Huye district, Rwanda


Resistance to first line treatment of Plasmodium falciparum poses a serious threat to global malaria control. This project aims at studying possible resistance or decreased sensitivity of Plasmodium falciparum to Artemisinin based therapies in the Huye district of Southern Rwanda. The parasites will be characterized using different in vivo and in vitro techniques for sensitivity testing and the newly established Ring Stage Survival Assay. In addition, host genetic factors influencing malaria and parasite clearance will be analyzed. 

Pinkus Tober-Lau 

Supervisor: PD Dr. med. Florian Kurth Medizinische Klinik m. S. Infektiologie & Pneumologie - Clinical Research Group in Tropical Medicine and Internationa


Post-treatment delayed hemolysis is common following oral artemisinin combination therapy of uncomplicated malaria


Artemisinins are the recommended first-line treatment for severe and uncomplicated malaria. Post-treatment haemolysis (PTH) is common in severe malaria treated with intravenous artesunate. We investigated PTH in patients with uncomplicated malaria receiving oral artemisinin-based combination therapy (ACT).